128 related articles for article (PubMed ID: 36002393)
1. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
Zhai Y; He K; Huang L; Shang X; Wang G; Yuan G; Han ZG
Liver Int; 2022 Nov; 42(11):2524-2537. PubMed ID: 36002393
[TBL] [Abstract][Full Text] [Related]
2. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
3. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
4. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
[TBL] [Abstract][Full Text] [Related]
5. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
6. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells.
Qin A; Qin Y; Lee J; Musket A; Ying M; Krenciute G; Marincola FM; Yao ZQ; Musich PR; Xie Q
J Transl Med; 2023 Oct; 21(1):682. PubMed ID: 37779207
[TBL] [Abstract][Full Text] [Related]
8. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma.
Xu X; Liu RF; Zhang X; Huang LY; Chen F; Fei QL; Han ZG
Mol Cancer Ther; 2012 Mar; 11(3):629-38. PubMed ID: 22238367
[TBL] [Abstract][Full Text] [Related]
9. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
[TBL] [Abstract][Full Text] [Related]
10. EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma.
Ma Y; Chen Y; Yan L; Cao HX; Han SY; Cui JJ; Wen JG; Zheng Y
Int J Med Sci; 2020; 17(10):1406-1414. PubMed ID: 32624697
[TBL] [Abstract][Full Text] [Related]
11. c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells
Huang X; Guo J; Li T; Jia L; Tang X; Zhu J; Tang Q; Feng Z
J Biomed Res; 2021 Dec; 36(1):10-21. PubMed ID: 35403606
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
13. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.
Wu Y; Chen D; Lu Y; Dong SC; Ma R; Tang WY; Wu JQ; Feng JF; Wu JZ
Cancer Gene Ther; 2022 Feb; 29(2):167-177. PubMed ID: 33514882
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.
Tseng HC; Xiong W; Badeti S; Yang Y; Ma M; Liu T; Ramos CA; Dotti G; Fritzky L; Jiang JG; Yi Q; Guarrera J; Zong WX; Liu C; Liu D
Nat Commun; 2020 Sep; 11(1):4810. PubMed ID: 32968061
[TBL] [Abstract][Full Text] [Related]
15. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I; Kalafateli M; Triantos C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473878
[TBL] [Abstract][Full Text] [Related]
17. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
18. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
Min J; Long C; Zhang L; Duan J; Fan H; Chu F; Li Z
Bioengineered; 2022 Apr; 13(4):9216-9232. PubMed ID: 35378051
[TBL] [Abstract][Full Text] [Related]
19. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
20. HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]